Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Disparities

Topic: Risk, prevention and care in population studies

Plain-language summary

Among 13,875 individuals with nonmissing VRF and outcome data with up to 30 years of follow-up (25% Black, 54% female), 179 developed PD at a mean age of 73.4 years, 94 developed PDD at a mean age of 79.2 years, and 1,791 developed dementia without PD at a mean age of 79.7 years. Midlife current smoking (hazard ratio [HR] 0.36, 95% CI 0.21-0.61) was significantly associated with a lower PD rate, independent of other risk factors and demographics. Midlife current smoking was also significantly associated with a lower rate of PDD (HR 0.41, 95% CI 0.18-0.95). Other VRFs were not associated with either PD or PDD. Smoking status in midlife was associated with lower rates of PD and PDD, but other VRFs had no association with PD or PDD. Further studies should evaluate changes of these VRFs over the life course and explore mechanisms for the observed associations.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 13,875 participants. This longitudinal study found that midlife current smoking was associated with lower rates of Parkinson disease and Parkinson disease-dementia, while other midlife vascular risk factors were not associated with either. Reported effect size: HR 0.41.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Johri, M., Morrill, V., Okine, D. N., Huang, X., Rosenthal, L. S., Seemiller, J., et al. (2025). Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia. Neurology. https://doi.org/10.1212/wnl.0000000000213931

Vancouver

Johri M, Morrill V, Okine DN, Huang X, Rosenthal LS, Seemiller J, et al. Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia. Neurology. 2025. doi:10.1212/wnl.0000000000213931. PMID: 40906974.

BibTeX

@article{johri2025-40906974,
  author  = {Johri, Mohini and Morrill, Valerie and Okine, Derrick N. and Huang, Xuemei and Rosenthal, Liana S. and Seemiller, Joseph and Shrestha, Srishti and Sullivan, Kevin and others},
  title   = {{Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia}},
  journal = {Neurology},
  year    = {2025},
  doi     = {10.1212/wnl.0000000000213931},
  pmid    = {40906974},
  url     = {https://doi.org/10.1212/wnl.0000000000213931}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This longitudinal study found that midlife current smoking was associated with lower rates of Parkinson disease and Parkinson disease-dementia, while other midlife vascular risk factors were not associated with either. The authors call for further studies to explore mechanisms for these observed associations, and the findings concern Parkinson disease rather than Alzheimer's disease treatment, cure, or prevention.

Study details

How this study scored 67/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 67 of 100.67 of 100 points earned33 not earned

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 4 / 4 13,875 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 7 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.3 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 3.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Rebecca F. Gottesman: h-index 92 (OpenAlex, whole career)
Institution's track record 3 / 3 National Institutes of Health: institution h-index 2,723 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 10 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40906974)
Free to read 2 / 2 Free to read
Total 67 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Disparities from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disparities

See all studies in Disparities →